CliffBio
small molecule

MONTELUKAST SODIUM

MONTELUKAST SODIUM

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameMONTELUKAST SODIUM
Active ingredientMONTELUKAST SODIUM
StrengthEQ 5MG BASE
Dosage formTABLET, CHEWABLE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2012
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.